File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore.

TitleA cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore.
Authors
Issue Date2004
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.com
Citation
Journal Of Clinical Gastroenterology, 2004, v. 38 n. 10 Suppl, p. S136-143 How to Cite?
AbstractGOALS: To estimate and compare the direct medical cost in the management of chronic hepatitis B (CHB) infection and its complications from the perspective of public health organizations in Hong Kong and Singapore. BACKGROUND: Hong Kong and Singapore are endemic hepatitis B virus areas with about 10% and 5%, respectively, of the population estimated as hepatitis B virus infected. STUDY: The medical histories of 660 patients with CHB who received medical services over 5 years from three major public hospitals in Hong Kong and Singapore were studied retrospectively. Costs were analyzed according to the five disease states and estimated in Hong Kong dollars (HKD) and Singapore dollars (SGD). RESULTS: In both Hong Kong and Singapore, the per-patient total annual cost increased with the severity of the disease. CHB cost HKD 6318 (US 810 dollars) in Hong Kong and SGD 718.15 (US 410.37 dollars) in Singapore. Compensated cirrhosis cost HKD 10,304 (US 1321 dollars) in Hong Kong and SGD 1,175.34 (US 671.62 dollars) in Singapore. Decompensated cirrhosis cost HKD 58,428 (US 7490 dollars) in Hong Kong and SGD 15,389.84 (US 8794.19 dollars) in Singapore. Hepatocellular carcinoma cost HKD 121,822 (US 15,618 dollars) in Hong Kong and SGD 12314.04 (US 7036.59 dollars) in Singapore. Each case of liver transplant was estimated to cost HKD 514,498 (US 65,961 dollars) in Hong Kong and SGD 86,369.28 (US 49,353.87 dollars) in Singapore. CHB in Hong Kong accounted for about 4% of the healthcare expenditure. CONCLUSION: This study confirms that CHB and its liver disease complications are a significant economic burden to the healthcare budgets of Hong Kong and Singapore, and indicates that effective therapy that arrests or reverses the progression of liver disease would be highly cost-effective.
Persistent Identifierhttp://hdl.handle.net/10722/171332
ISSN
2015 Impact Factor: 3.163
2015 SCImago Journal Rankings: 1.274
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, SCen_US
dc.contributor.authorOng, SCen_US
dc.contributor.authorLim, SGen_US
dc.contributor.authorYeoh, KGen_US
dc.contributor.authorKwong, KSen_US
dc.contributor.authorLee, Ven_US
dc.contributor.authorLee, Wen_US
dc.contributor.authorLau, Jen_US
dc.contributor.authorWong, Ien_US
dc.contributor.authorKung, Nen_US
dc.contributor.authorLeung, WTen_US
dc.contributor.authorChan, HLen_US
dc.contributor.authorChan, FKen_US
dc.contributor.authorSung, JJen_US
dc.contributor.authorLee, KKen_US
dc.date.accessioned2012-10-30T06:13:27Z-
dc.date.available2012-10-30T06:13:27Z-
dc.date.issued2004en_US
dc.identifier.citationJournal Of Clinical Gastroenterology, 2004, v. 38 n. 10 Suppl, p. S136-143en_US
dc.identifier.issn0192-0790en_US
dc.identifier.urihttp://hdl.handle.net/10722/171332-
dc.description.abstractGOALS: To estimate and compare the direct medical cost in the management of chronic hepatitis B (CHB) infection and its complications from the perspective of public health organizations in Hong Kong and Singapore. BACKGROUND: Hong Kong and Singapore are endemic hepatitis B virus areas with about 10% and 5%, respectively, of the population estimated as hepatitis B virus infected. STUDY: The medical histories of 660 patients with CHB who received medical services over 5 years from three major public hospitals in Hong Kong and Singapore were studied retrospectively. Costs were analyzed according to the five disease states and estimated in Hong Kong dollars (HKD) and Singapore dollars (SGD). RESULTS: In both Hong Kong and Singapore, the per-patient total annual cost increased with the severity of the disease. CHB cost HKD 6318 (US 810 dollars) in Hong Kong and SGD 718.15 (US 410.37 dollars) in Singapore. Compensated cirrhosis cost HKD 10,304 (US 1321 dollars) in Hong Kong and SGD 1,175.34 (US 671.62 dollars) in Singapore. Decompensated cirrhosis cost HKD 58,428 (US 7490 dollars) in Hong Kong and SGD 15,389.84 (US 8794.19 dollars) in Singapore. Hepatocellular carcinoma cost HKD 121,822 (US 15,618 dollars) in Hong Kong and SGD 12314.04 (US 7036.59 dollars) in Singapore. Each case of liver transplant was estimated to cost HKD 514,498 (US 65,961 dollars) in Hong Kong and SGD 86,369.28 (US 49,353.87 dollars) in Singapore. CHB in Hong Kong accounted for about 4% of the healthcare expenditure. CONCLUSION: This study confirms that CHB and its liver disease complications are a significant economic burden to the healthcare budgets of Hong Kong and Singapore, and indicates that effective therapy that arrests or reverses the progression of liver disease would be highly cost-effective.en_US
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.comen_US
dc.relation.ispartofJournal of clinical gastroenterologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshCosts And Cost Analysisen_US
dc.subject.meshHepatitis B, Chronic - Complications - Economics - Therapyen_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSingaporeen_US
dc.titleA cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore.en_US
dc.typeArticleen_US
dc.identifier.emailWong, I:wongick@hku.hken_US
dc.identifier.authorityWong, I=rp01480en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1097/00004836-200411003-00004-
dc.identifier.pmid15602161-
dc.identifier.scopuseid_2-s2.0-21644434760en_US
dc.identifier.volume38en_US
dc.identifier.issue10 Supplen_US
dc.identifier.spageS136en_US
dc.identifier.epage143en_US
dc.identifier.isiWOS:000224797400004-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLi, SC=7409238460en_US
dc.identifier.scopusauthoridOng, SC=8453776300en_US
dc.identifier.scopusauthoridLim, SG=7404081127en_US
dc.identifier.scopusauthoridYeoh, KG=7004891021en_US
dc.identifier.scopusauthoridKwong, KS=8453776600en_US
dc.identifier.scopusauthoridLee, V=7402507380en_US
dc.identifier.scopusauthoridLee, W=7407084623en_US
dc.identifier.scopusauthoridLau, J=26643560600en_US
dc.identifier.scopusauthoridWong, I=7102513915en_US
dc.identifier.scopusauthoridKung, N=6603573627en_US
dc.identifier.scopusauthoridLeung, WT=36956842300en_US
dc.identifier.scopusauthoridChan, HL=25722700100en_US
dc.identifier.scopusauthoridChan, FK=7202586434en_US
dc.identifier.scopusauthoridSung, JJ=35405352400en_US
dc.identifier.scopusauthoridLee, KK=7501515004en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats